Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
- PMID: 30891370
- PMCID: PMC6415980
- DOI: 10.7759/cureus.3720
Ticagrelor-induced Angioedema After Percutaneous Coronary Intervention in a Patient with a History of Ischemic Stroke and Low Response to Clopidogrel: A Rare Dilemma
Abstract
Dual antiplatelet therapy (DAPT) is widely recognized as the mainstay of treatment after percutaneous coronary intervention (PCI). Premature discontinuation may pose a risk of in-stent thrombosis, acute myocardial infarction, and death. With the increased usage of antiplatelet agents, increased attention has been drawn to their potential allergic reactions. A 66-year-old male with a history of coronary artery disease and ischemic stroke was admitted with worsening severity angina for cardiac catheterization. He was on dual antiplatelet agents, clopidogrel, and aspirin prior to admission. He had PCI and a drug-eluting stent deployment to the culprit vessel. Due to low responsiveness to clopidogrel, he was started on ticagrelor, as prasugrel was contraindicated due to the history of ischemic stroke. A few hours after ticagrelor initiation, he developed shortness of breath, swelling of the throat and tongue, and was diagnosed with angioedema. He didn't have any prior reported history of allergy to any medications to the contrast medium or heparin. The offending medication, ticagrelor, was discontinued. He was managed with intravenous steroids and antihistamines. After the resolution of angioedema, he was discharged with double the dose of clopidogrel in addition to aspirin. The patient did not have any ischemic symptoms or coronary events for the following six-month period of follow-up. The case highlights a relatively rare side effect of ticagrelor. Health care providers should be vigilant about the angioedema following ticagrelor administration. In our patient, it was effectively managed by discontinuing the offending medication and the administration of steroids and histamine blockers. The recovery was prompt, without any serious untoward effects. The DAPT was changed to clopidogrel, double the conventional dose, in addition to aspirin.
Keywords: angioedema; dual antiplatelet therapy; ticagrelor.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
Ticagrelor: A Rare, Delayed Case of Angioedema.Cureus. 2023 May 5;15(5):e38606. doi: 10.7759/cureus.38606. eCollection 2023 May. Cureus. 2023. PMID: 37288188 Free PMC article.
-
High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT.Int J Cardiol. 2018 Oct 1;268:11-17. doi: 10.1016/j.ijcard.2018.03.116. Epub 2018 May 23. Int J Cardiol. 2018. PMID: 29801763 Clinical Trial.
-
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.Circ Cardiovasc Qual Outcomes. 2019 Jan;12(1):e004945. doi: 10.1161/CIRCOUTCOMES.118.004945. Circ Cardiovasc Qual Outcomes. 2019. PMID: 30606052
-
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis.BMC Pharmacol Toxicol. 2018 Sep 3;19(1):54. doi: 10.1186/s40360-018-0247-9. BMC Pharmacol Toxicol. 2018. PMID: 30176938 Free PMC article.
-
Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.Curr Pharm Des. 2018;24(4):465-477. doi: 10.2174/1381612824666180108121834. Curr Pharm Des. 2018. PMID: 29308737 Review.
Cited by
-
Ticagrelor Induced Angioedema Following Carotid Artery Stenting.Neurohospitalist. 2022 Jul;12(3):550-552. doi: 10.1177/19418744221097353. Epub 2022 Apr 23. Neurohospitalist. 2022. PMID: 35755229 Free PMC article.
-
Ticagrelor: A Rare, Delayed Case of Angioedema.Cureus. 2023 May 5;15(5):e38606. doi: 10.7759/cureus.38606. eCollection 2023 May. Cureus. 2023. PMID: 37288188 Free PMC article.
References
-
- Stent thrombosis redux — the FDA perspective. Farb A, Boam AB. N Engl J Med. 2007;356:984–987. - PubMed
-
- Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. N Engl J Med. 2001;345:494–502. - PubMed
-
- Prasugrel versus clopidogrel in patients with acute coronary syndromes. Wiviott SD, Braunwald E, McCabe CH, et al. N Engl J Med. 2007;357:2001–2015. - PubMed
-
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes. Wallentin L, Becker RC, Budaj A, et al. N Engl J Med. 2009;361(11):1045–1057. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous